Search

• GSK commits further funding to advance bioelectronics research with creation of 5 million Innovation Challenge Fund

  Media

  GSK announced, $5 million ICF to encourage and advance collaborative research as part of its effort to develop bioelectronic medicines.

  https://www.gsk.com/en-gb/media/press-releases/gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund/

  First published: 30 September 2014

• Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris

  Media

  Stiefel, announced phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris

  https://www.gsk.com/en-gb/media/press-releases/stiefel-a-gsk-company-announces-start-of-phase-iii-study-of-subcutaneous-ofatumumab-for-pemphigus-vulgaris/

  First published: 07 October 2014

• Publication of Circular and Notice of General Meeting relating to the proposed major transaction with Novartis

  Media

  GSK announced a major conditional transaction with Novartis involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/publication-of-circular-and-notice-of-general-meeting-relating-to-the-proposed-major-transaction-with-novartis/

  First published: 24 November 2014

• GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

  Media

  GSK announced that the FDA has approved umeclidinium as treatment of airflow obstruction in patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/

  First published: 30 April 2014

• ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention

  Media

  First injectable to be studied for efficacy in pre-exposure prophylaxis

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/

  First published: 20 December 2016

• GSK leads Access to Medicine Index 2016

  Media

  GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.

  https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2016/

  First published: 14 November 2016

• GSK and Adaptimmune expand strategic immunotherapy collaboration

  Media

  GSK and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-expand-strategic-immunotherapy-collaboration/

  First published: 02 February 2016

• GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL

  Media

  GSK & GEN announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a phase III study, PROLONG (OMB 112517)

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-interim-result-for-phase-iii-study-of-ofatumumab-as-maintenance-therapy-for-relapsed-cll/

  First published: 31 July 2014

• GSK and Genmab receive FDA approval for Arzerra® (ofatumumab)

  Media

  GSK and Genmab announced today that CHMP of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra-ofatumumab/

  First published: 23 May 2014

• GSK and Genmab receive FDA approval for Arzerra

  Media

  GSK & GEN announced today that the FDA has approved a sBLA for Arzerra® (ofatumumab) for CLL

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra/

  First published: 17 April 2014